Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Ticlopidine on Esketamine PK
NCT03298906Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of esketamine in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at Day 1, Area Under the Plasma Concentration-time Curve From Time Zero to Infinite Time at Day 1 and 1 more. Started Sep 2017; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03298906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03298906.